Question-and-Answer Session
Operator
Ladies and gentlemen (Operator Instruction)
Gerald Proehl
While we are waiting for questions, I would like to inform you that we will be presenting at the Rodman & Renshaw Tenth Annual Healthcare Conference, taking place at the New York Palace Hotel on November 12, at 9:55am eastern time. We invite you to meet with us in person if you are attending the conference. If you are unable to attend, a web cast of our corporate presentation will be available on the Santarus website. Okay operator, we are ready for the first question.
Operator
Your first question comes from Annabel Samimy – UBS
Annabel Samimy – UBS
Just have a quick question regarding the NDA for the tablet formulation of ZEGERID; can you just remind us again how it is different than the capsule?
Gerald Proehl
The tablet product has multiple buffers as part of the product; there are some other features that would differentiate it for the capsule. At this point in time for competitive reasons, we are not disclosing those other features, but we will certainly at the time of approval.
Annabel Samimy – UBS
Okay. And you said, you are going to file the NDA, when?
Gerald Proehl
On the first quarter of 2009.
Annabel Samimy – UBS
Okay. Are you doing this strictly as a life cycle management deal or is it more to offer more formulations to differentiation for one single reason or another, like some patients do not like the capsule. Can you give the reason for providing the tablet?
Gerald Proehl
It is obviously part of a lifecycle management strategy. We also think that the swallowable tablet will offer patient some other added advantages that the capsules does not.
Annabel Samimy – UBS
And there are descriptions of those advantages?
Gerald Proehl
Not at this point.
Operator
Your next question comes from Ian Sanderson – Cowen and Company
Ian Sanderson – Cowen and Company
Actually, a follow up to Annabel’s on the ZEGERID tablet. Will that formulation be covered by the new 772 patent or the buffer is different enough that it falls outside the patent?
Gerald Proehl
It will be covered under the 772 patent, and yes.
Ian Sanderson – Cowen and Company
Debbie, could you give us any further details on how much the ZEGERID price was raised earlier this year? And also, your guidance implies a decline in the SG&A spending in Q4 versus Q3 and maybe if you could talk about where those savings might come from?
- To read the full transcript on Seeking Alpha, click here »
